Multimodal Pre-Surgical Optimization for Obese Endometrial Cancer Patients

Obesity is a significant risk factor for endometrial cancer and can complicate surgical outcomes. Patients with a BMI ≥35 and early-stage endometrial cancer or atypical endometrial hyperplasia face increased surgical risks and often have poorer prognoses. Current approaches lack comprehensive pre-surgical optimization strategies that address both metabolic health and tumor burden, leaving a critical gap in improving patient outcomes and potentially enabling less invasive treatments.

While this study is not yet recruiting, it aims to demonstrate significant improvements in both metabolic and oncological outcomes. Researchers anticipate observing a substantial reduction in body weight, potentially a 10-15% average decrease, alongside improvements in insulin sensitivity and other metabolic markers due to GLP-1 agonist therapy. The intervention is also expected to induce a favorable pathological response in endometrial lesions, with a target of 40-60% complete or partial regression. > The most critical anticipated finding is the potential for this multimodal approach to significantly improve disease regression and metabolic health, thereby facilitating less invasive surgical options and enhancing overall patient prognosis. This comprehensive strategy is designed to offer a quantitative advantage over standard pre-surgical care, though direct comparison data will emerge post-study.